PE20140252A1 - ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf - Google Patents

((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf

Info

Publication number
PE20140252A1
PE20140252A1 PE2013000789A PE2013000789A PE20140252A1 PE 20140252 A1 PE20140252 A1 PE 20140252A1 PE 2013000789 A PE2013000789 A PE 2013000789A PE 2013000789 A PE2013000789 A PE 2013000789A PE 20140252 A1 PE20140252 A1 PE 20140252A1
Authority
PE
Peru
Prior art keywords
indazol
vinyl
dichloropidin
fgrf
etoxy
Prior art date
Application number
PE2013000789A
Other languages
English (en)
Inventor
Benjamin Alan Diseroad
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140252(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20140252A1 publication Critical patent/PE20140252A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA AL COMPUESTO MONOHIDRATO DE ((R)-(E)-2-(4-(2-(5-(1-(3,5-DICLOROPIRIDIN-4-IL)ETOXI)-1H-INDAZOL-3-IL)VINIL)-1H-PIRAZOL-1-IL)ETANOL CRISTALINO QUE PRESENTA UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X QUE COMPRENDE PICOS A 14,65, 3,54, 12,51 Y 19,16 (2 THETA +/- 0,1�). TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DEL CANCER
PE2013000789A 2010-10-05 2011-09-29 ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf PE20140252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38991110P 2010-10-05 2010-10-05

Publications (1)

Publication Number Publication Date
PE20140252A1 true PE20140252A1 (es) 2014-03-12

Family

ID=44999860

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000789A PE20140252A1 (es) 2010-10-05 2011-09-29 ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf

Country Status (35)

Country Link
US (1) US8530665B2 (es)
EP (1) EP2625175B1 (es)
JP (1) JP5940547B2 (es)
KR (1) KR101527661B1 (es)
CN (1) CN103153983B (es)
AR (1) AR083091A1 (es)
AU (1) AU2011312485B2 (es)
BR (1) BR112013006336A2 (es)
CA (1) CA2813329C (es)
CL (1) CL2013000884A1 (es)
CO (1) CO6710911A2 (es)
DK (1) DK2625175T3 (es)
DO (1) DOP2013000072A (es)
EA (1) EA021817B1 (es)
EC (1) ECSP13012539A (es)
ES (1) ES2558777T3 (es)
HK (1) HK1184147A1 (es)
HR (1) HRP20151299T1 (es)
HU (1) HUE026379T2 (es)
IL (1) IL224850A (es)
JO (1) JO3062B1 (es)
MA (1) MA34552B1 (es)
ME (1) ME02307B (es)
MX (1) MX2013003907A (es)
NZ (1) NZ608482A (es)
PE (1) PE20140252A1 (es)
PL (1) PL2625175T3 (es)
PT (1) PT2625175E (es)
RS (1) RS54457B1 (es)
SG (1) SG188286A1 (es)
SI (1) SI2625175T1 (es)
TW (1) TWI418554B (es)
UA (1) UA111725C2 (es)
WO (1) WO2012047699A1 (es)
ZA (1) ZA201301560B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111705099B (zh) * 2020-07-01 2022-03-08 天津药明康德新药开发有限公司 一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法
TW202241911A (zh) * 2020-12-17 2022-11-01 美商榮山醫藥股份有限公司 大環化合物及其用途
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
SG174632A1 (en) * 2000-09-11 2011-10-28 Novartis Vaccines & Diagnostic Quinolinone derivatives
EP1510516A4 (en) 2002-05-31 2005-11-02 Eisai Co Ltd PYRAZOL COMPOUND AND MEDICAL COMPOSITION CONTAINING THEM
KR100816960B1 (ko) * 2004-03-17 2008-03-25 화이자 인코포레이티드 2,5-디메틸-2ｈ-피라졸-3-카르복실산｛2-플루오로-5-[3-((ｅ)-2-피리딘-2-일-비닐)-1ｈ-인다졸-6-일아미노]-페닐｝-아미드의 다형성 및 무정질 형태
JP4746299B2 (ja) * 2004-07-16 2011-08-10 ジュズ インターナショナル ピーティーイー エルティーディー 金属酸化物粉末の製造方法
JP2006163651A (ja) 2004-12-03 2006-06-22 Sony Computer Entertainment Inc 表示装置、表示装置の制御方法、プログラム及びフォントデータ
US20060160863A1 (en) * 2005-01-05 2006-07-20 Agouron Pharmaceuticals, Inc. Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
NZ580126A (en) * 2007-04-05 2012-03-30 Pfizer Prod Inc Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
AR078411A1 (es) * 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende

Also Published As

Publication number Publication date
ES2558777T3 (es) 2016-02-08
IL224850A (en) 2016-09-29
JP5940547B2 (ja) 2016-06-29
ME02307B (me) 2016-06-20
HK1184147A1 (en) 2014-01-17
MA34552B1 (fr) 2013-09-02
CA2813329A1 (en) 2012-04-12
SI2625175T1 (sl) 2016-01-29
CN103153983B (zh) 2014-11-05
CA2813329C (en) 2015-05-26
PL2625175T3 (pl) 2016-04-29
JP2013538875A (ja) 2013-10-17
TWI418554B (zh) 2013-12-11
HUE026379T2 (en) 2016-06-28
BR112013006336A2 (pt) 2019-09-24
EP2625175B1 (en) 2015-11-18
EA021817B1 (ru) 2015-09-30
DOP2013000072A (es) 2013-08-15
CL2013000884A1 (es) 2013-10-18
AU2011312485A1 (en) 2013-03-07
US8530665B2 (en) 2013-09-10
ZA201301560B (en) 2014-08-27
WO2012047699A1 (en) 2012-04-12
NZ608482A (en) 2014-03-28
CO6710911A2 (es) 2013-07-15
PT2625175E (pt) 2016-01-22
ECSP13012539A (es) 2013-06-28
RS54457B1 (en) 2016-06-30
SG188286A1 (en) 2013-04-30
KR101527661B1 (ko) 2015-06-09
KR20130052680A (ko) 2013-05-22
DK2625175T3 (en) 2016-02-01
CN103153983A (zh) 2013-06-12
HRP20151299T1 (hr) 2016-01-01
US20120083511A1 (en) 2012-04-05
AU2011312485B2 (en) 2014-09-04
JO3062B1 (ar) 2017-03-15
MX2013003907A (es) 2013-06-03
EP2625175A1 (en) 2013-08-14
TW201249826A (en) 2012-12-16
UA111725C2 (uk) 2016-06-10
EA201390275A1 (ru) 2013-07-30
AR083091A1 (es) 2013-01-30

Similar Documents

Publication Publication Date Title
PE20140252A1 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf
PE20120812A1 (es) Compuestos vinil indazolilo
CO7160104A2 (es) Inhibidores de virus de hepatitis c
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
NZ621221A (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
IN2015DN00185A (es)
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
BR112013029999A2 (pt) derivados de tiazol
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
ECSP099565A (es) Compuesto de 2-amino pirimidina
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
ECSP10010167A (es) Composiciones oftálmicas novedosas
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
ECSP088781A (es) Derivados de benzimidazol
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2011000292A1 (es) Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica.

Legal Events

Date Code Title Description
FC Refusal